Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs which are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.
Subscribe to our email newsletter
Biogen Idec will make an initial payment of $32.5m and up to $395m in contingent payments.
Biogen Idec and Neurimmune said that the acquisition builds on a 2007 agreement between the two companies to explore human antibodies against beta-amyloid for the treatment and prevention of Alzheimer’s disease.
The three pre-clinical candidates complement the existing research collaboration by targeting three different neurotoxic proteins, the mis-folding of which is thought to be the cause of many neurodegenerative diseases.
Biogen Idec will be responsible for the development of the pre-clinical candidates and the commercialization of all products.
However, Neurimmune will be responsible for additional scientific activities with respect to the lead candidates as well as the discovery of back-up candidates, utilizing its Reverse Translational Medicine technology platform.
Neurimmune retains the right to use its platform for creating therapeutic antibody products outside the scope of its agreement with Biogen Idec.
Biogen Idec Neurology Research and Development senior vice president Alfred Sandrock said that Neurimmune continues to impress them with their ability to translate scientific insights into innovative antibodies for the potential treatment and prevention of many neurodegenerative diseases.
Neurimmune founder and Director Roger Nitsch said that they are pleased that Biogen Idec decided to acquire these candidate therapeutics for neurodegenerative diseases.
"With its expertise in the development, manufacturing and marketing of therapeutic antibodies for neurological diseases, Biogen Idec is the perfect strategic fit to drive the successful development of Neurimmune’s antibodies.